Hikma Pharmaceuticals PLC (LSE:HIK) entered into an agreement to acquire Medlac Pharma Italy Co. Ltd. for $17 million on November 7, 2018. The acquisition by Hikma Pharmaceuticals also includes all employees of Medlac Pharma. Ben Atwell and Brett Pollard of FTI Consulting LLP acted as financial advisors for Hikma Pharmaceuticals. Chris McGaffin and Eilene Teh of Slaughter and May acted as legal advisor to Hikma Pharmaceuticals. Ernst & Young UK, Investment Banking Arm acted as financial and due diligence provider to Hikma. Hikma Pharmaceuticals PLC (LSE:HIK) completed the acquisition of Medlac Pharma Italy Co. Ltd. on January 2, 2019. The total consideration amount includes initial upfront cash payment of $8 million and is not expected to exceed $17 million. The consideration includes deferred and contingent consideration payable on successful achievement of certain conditions and milestones.